233 related articles for article (PubMed ID: 19357772)
1. Integrated functional, gene expression and genomic analysis for the identification of cancer targets.
Iorns E; Lord CJ; Grigoriadis A; McDonald S; Fenwick K; Mackay A; Mein CA; Natrajan R; Savage K; Tamber N; Reis-Filho JS; Turner NC; Ashworth A
PLoS One; 2009; 4(4):e5120. PubMed ID: 19357772
[TBL] [Abstract][Full Text] [Related]
2. Functional kinomics identifies candidate therapeutic targets in head and neck cancer.
Moser R; Xu C; Kao M; Annis J; Lerma LA; Schaupp CM; Gurley KE; Jang IS; Biktasova A; Yarbrough WG; Margolin AA; Grandori C; Kemp CJ; Méndez E
Clin Cancer Res; 2014 Aug; 20(16):4274-88. PubMed ID: 25125259
[TBL] [Abstract][Full Text] [Related]
3. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.
Harris PS; Venkataraman S; Alimova I; Birks DK; Balakrishnan I; Cristiano B; Donson AM; Dubuc AM; Taylor MD; Foreman NK; Reigan P; Vibhakar R
Mol Cancer; 2014 Mar; 13():72. PubMed ID: 24661910
[TBL] [Abstract][Full Text] [Related]
4. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.
Porter CC; Kim J; Fosmire S; Gearheart CM; van Linden A; Baturin D; Zaberezhnyy V; Patel PR; Gao D; Tan AC; DeGregori J
Leukemia; 2012 Jun; 26(6):1266-76. PubMed ID: 22289989
[TBL] [Abstract][Full Text] [Related]
5. Functional genomics to explore cancer cell vulnerabilities.
Kahle KT; Kozono D; Ng K; Hsieh G; Zinn PO; Nitta M; Chen CC
Neurosurg Focus; 2010 Jan; 28(1):E5. PubMed ID: 20043720
[TBL] [Abstract][Full Text] [Related]
6. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.
Creevey L; Ryan J; Harvey H; Bray IM; Meehan M; Khan AR; Stallings RL
Mol Cancer; 2013 Mar; 12():23. PubMed ID: 23531080
[TBL] [Abstract][Full Text] [Related]
8. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells.
Pappano WN; Zhang Q; Tucker LA; Tse C; Wang J
BMC Cancer; 2014 Jun; 14():430. PubMed ID: 24927813
[TBL] [Abstract][Full Text] [Related]
9. Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells.
Jaiswal A; Peddinti G; Akimov Y; Wennerberg K; Kuznetsov S; Tang J; Aittokallio T
Genome Med; 2017 Jun; 9(1):51. PubMed ID: 28569207
[TBL] [Abstract][Full Text] [Related]
10. Tumour suppressive effects of WEE1 gene silencing in breast cancer cells.
Ghiasi N; Habibagahi M; Rosli R; Ghaderi A; Yusoff K; Hosseini A; Abdullah S; Jaberipour M
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6605-11. PubMed ID: 24377575
[TBL] [Abstract][Full Text] [Related]
11. Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target.
Aka Y; Karakas B; Acikbas U; Basaga H; Gul O; Kutuk O
Int J Biochem Cell Biol; 2021 Aug; 137():106028. PubMed ID: 34171479
[TBL] [Abstract][Full Text] [Related]
12. Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.
Ou O; Huppi K; Chakka S; Gehlhaus K; Dubois W; Patel J; Chen J; Mackiewicz M; Jones TL; Pitt JJ; Martin SE; Goldsmith P; Simmons JK; Mock BA; Caplen NJ
Cancer Lett; 2014 Nov; 354(2):336-47. PubMed ID: 25193464
[TBL] [Abstract][Full Text] [Related]
13. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
[TBL] [Abstract][Full Text] [Related]
14. A Synthetic Dosage Lethal Genetic Interaction Between CKS1B and PLK1 Is Conserved in Yeast and Human Cancer Cells.
Reid RJ; Du X; Sunjevaric I; Rayannavar V; Dittmar J; Bryant E; Maurer M; Rothstein R
Genetics; 2016 Oct; 204(2):807-819. PubMed ID: 27558135
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas.
Butz H; Likó I; Czirják S; Igaz P; Khan MM; Zivkovic V; Bálint K; Korbonits M; Rácz K; Patócs A
J Clin Endocrinol Metab; 2010 Oct; 95(10):E181-91. PubMed ID: 20668041
[TBL] [Abstract][Full Text] [Related]
16. RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells.
Zhou XK; Tang SS; Yi G; Hou M; Chen JH; Yang B; Liu JF; He ZM
World J Gastroenterol; 2011 Aug; 17(32):3700-8. PubMed ID: 21990951
[TBL] [Abstract][Full Text] [Related]
17. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein.
Kobos R; Nagai M; Tsuda M; Merl MY; Saito T; Laé M; Mo Q; Olshen A; Lianoglou S; Leslie C; Ostrovnaya I; Antczak C; Djaballah H; Ladanyi M
J Pathol; 2013 Apr; 229(5):743-754. PubMed ID: 23288701
[TBL] [Abstract][Full Text] [Related]
18. Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen.
Morgan-Lappe SE; Tucker LA; Huang X; Zhang Q; Sarthy AV; Zakula D; Vernetti L; Schurdak M; Wang J; Fesik SW
Cancer Res; 2007 May; 67(9):4390-8. PubMed ID: 17483353
[TBL] [Abstract][Full Text] [Related]
19. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
[TBL] [Abstract][Full Text] [Related]
20. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.
Wang H; Han H; Von Hoff DD
Cancer Res; 2006 Oct; 66(19):9722-30. PubMed ID: 17018631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
